This inventor holds 1 USPTO granted patent. Top assignees: Eisai Company, Limited, Sansho Co., Ltd., Sekisui Kagaku Kogyo Kabushiki Kaisha. Active years: 1993.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:

Years Active: 1993
Title: The Innovative Contributions of Tsutomu Negama
Introduction: Tsutomu Negama is a prominent inventor from Osaka, Japan, known for his significant contributions to the field of pharmacology. With a focus on improving drug absorption, Negama has made strides that benefit medical treatments, showcasing the important intersection of science and innovation.
Latest Patents: Tsutomu Negama holds a noteworthy patent titled "Percutaneously Absorbable Crosslinked Polyvinylpyrrolidone Eperisone." This pharmacological composition aims for percutaneous administration to human patients, comprising a pharmacologically effective amount of eperisone or a related salt, tolperisone or its salt, and a water-swellable crosslinked polyvinylpyrrolidone. His invention demonstrates improved percutaneous absorption, enhancing the effectiveness of drug delivery systems.
Career Highlights: Throughout his career, Negama has worked with reputable companies in the pharmaceutical industry. Notably, he has been associated with Sekisui Kagaku Kogyo Co., Ltd. and Sansho Co., Ltd., where he applied his expertise to develop innovative solutions that contribute to health and wellness.
Collaborations: During his professional journey, Negama has collaborated with esteemed colleagues such as Masato Azuma and Mitsuhiro Yoshida. These partnerships have fostered a creative environment that promotes innovation and the development of groundbreaking pharmaceutical compositions.
Conclusion: Tsutomu Negama's commitment to innovation in pharmaceutical science is evident in his patent achievements and collaborative efforts with industry professionals. His work continues to be influential, enhancing drug delivery methods and improving patient outcomes.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile